Outcomes of Patients on ALK Inhibitor Therapy in NHS Tayside Scotland UK

Lung cancer is the most frequently diagnosed cancer in Scotland, but ALK and ROS 1 mutated lung cancer is rare. Targeted ALK therapy can provide durable responses with good tolerability. The outcomes of these patients in NHST are currently unknown and an audit was performed to clarify. Aim: To study the use and outcomes of ALK inhibitors in ALK mutated and Ros 1 mutated NSCLCa in NHST.